+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Microbiome Manufacturing Market (3rd Edition): Industry Trends and Global Forecasts, till 2035: Distribution by Type of Product Manufactured, Type of Formulation, Type of Primary Packaging Used, Scale of Operation, Company Size, Key Geographical Regions and Leading Developers

  • PDF Icon

    Report

  • 286 Pages
  • February 2024
  • Region: Global
  • Roots Analysis
  • ID: 5941152

The analyst believes that a lot of start-ups have entered the market, however, only a few companies have established their own facilities to manufacture microbiome-based products. This is primarily due to the fact that the cost of establishing an LBP production facility is high, and therefore, requires significant capital investment. As a result, companies have demonstrated preference to outsource manufacturing operations.

The global microbiome manufacturing market size is estimated to grow from USD 27 billion in 2023 to USD 187 billion by 2035, representing a CAGR of 17% during the forecast period 2023-2035. The human body is known to harbor numerous communities of microbes, including both beneficial and harmful species, which are collectively referred to as microbiota. Likewise, the ecological system of commensal, symbiotic, and pathogenic microorganisms that reside within a host system is called the microbiome. Given the role of the microbiota in both disease development and pathogenesis, the concept of microbiome-based therapeutics has, over time, piqued the interest of the medical science community.

In fact, the last two decades have witnessed several developments in the field of microbiome therapy research and their therapeutic applications. Live biotherapeutic products (LBP), a class of microbiome therapy, involve the use of live microorganisms, such as bacteria, viruses, or fungi, to prevent or treat various disease conditions. LBPs are specifically designed for therapeutic purposes and are regulated as medicinal products or biologics in many countries. These therapeutic modalities consist of well-characterized specific strains of microorganisms that are extensively researched for their intended medical applications, followed by rigorous testing and clinical trials to demonstrate safety and efficacy for treating or preventing specific medical condition. Further, the microbiome-based therapeutic approach has the potential to profile the microbiome composition of the patient using gene sequencing; this will lead to the development of tailored treatment options.

It is worth highlighting that in November 2022, the US Food and Drug Administration (FDA) approved the first microbiome-based therapy, RBX2660 (developed by Rebiotix) for the treatment of recurrent Clostridium difficile infection.

With the advancement of several promising microbiome-based live biotherapeutic products through clinical pipelines, this upcoming therapeutic segment is anticipated to become one of the fastest growing global market within the pharmaceutical industry in the coming years. Despite several developments in the field of microbiome-based therapies, and decades of experience growing bacteria to produce biologics, the biotech industry is still ill-equipped for microbiome manufacturing, including live biotherapeutic products manufacturing.

Manufacturing of live bacterial therapies at large scale is fraught with various challenges. Some of the key concerns of contemporary innovators include prolonged development timelines, stringent temperature control requirements, complex engineering of diverse aerobic / anaerobic strains (depending on the type of microbe) and inconsistencies related to quality attributes of the final product. Therefore, outsourcing of microbiome therapeutics manufacturing to CMOs and CDMOs emerged as a lucrative option for human microbiome therapy developers to overcome the existing manufacturing issues. These CMOs and CDMOs (which are a part of the broader biologics contract manufacturing market) are increasingly focusing on enhancing their offerings by incorporating novel technologies in order to streamline microbiome manufacturing processes, increase production efficiency, and improve quality. This will further propel the microbiome market as well as the microbiome manufacturing market.

Microbiome Manufacturing Market Key Market Insights

The report features an extensive study of the current market landscape, market size and future opportunities for the microbiome manufacturing companies, including those involved in live biotherapeutic manufacturing, during the given forecast period. Further, this microbiome manufacturing market analysis highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the microbiome manufacturing market report are briefly discussed below.

Competitive Landscape of Microbiome Manufacturing Companies

The microbiome manufacturing market features a mix of large, mid-sized and small in-house players and contract manufacturing organizations that are engaged in the production of microbiome therapy across different scales of operations, such as preclinical, clinical, and commercial. Currently, 50% of the microbiome therapy contract manufacturers offer services for both API and FDF manufacturing; notable examples (in alphabetical order) include Arranta Bio, BacThera, Biose, Capsugel and Cerbios-Pharma. In addition, majority of the microbiome companies offer probiotic manufacturing services on a contract basis.

It is worth mentioning several microbiome-based products, including fecal microbiota transplantation (FMT) procedures, and dietary supplements, have been approved in the US; of which probiotics / prebiotics are the most commonly available formulations in the market as they do not require marketing approval from the regulatory agencies. Notably, in April 2023, SER-109, a microbiome-based first oral therapy developed by Seres Therapeutics for the prevention of recurring Clostridium difficile infection, received marketing approval from the FDA. The growing demand for novel microbiome therapeutics, approvals from various regulatory bodies and technological advancements in order to streamline the manufacturing process, are expected to drive the microbiome manufacturing market growth during the forecast period.

Clinical Trials Analysis: Close to 170 Trials are Evaluating Microbiome Therapeutics to Treat Various Infectious Diseases and Oncological Disorders

Over the years, microbiome companies involved in the manufacturing of microbiome therapeutics have made significant efforts to conduct clinical trials for evaluating the efficacy of microbiome therapies targeting various disorders, including infectious diseases (bacterial vaginosis, clostridium difficile infection, COVID-19, cystic fibrosis, tinea pedis and urinary tract infections), neurological disorders (autism, bipolar depression, Parkinson’s disease, stroke) and oncological disorders (advanced malignant solid tumor, breast cancer, colon cancer, gastric cancer, melanoma and non-small cell lung cancer). Close to 170 clinical trials have been conducted across different geographical regions to evaluate various microbiome therapies, of which, majority (70%) were registered in North America. Further, the maximum number of patients (10,138) were observed to be enrolled in clinical trials conducted in North America, which account for 52% of the overall enrollment. It is worth mentioning that AOBiome is conducting the maximum number of trials in this industry for different dermatological, respiratory and CNS disorders. In addition, VE303 (developed by Vedanta Biosciences) for the treatment of recurrent Clostridium difficile infection has demonstrated positive results in the Phase II clinical trials.

Market Trends Analysis: Partnerships and Collaborations have Fueled Microbiome Manufacturing Market Growth

Several stakeholders have been forging alliances with other industry / non-industry players in the microbiome therapeutics contract manufacturing industry. It is worth highlighting that since 2018, over 50 strategic partnerships have been established in this domain, of which the majority are focused on research, product development, and technology utilization. In June 2023, Biose entered into a technology utilization agreement with SBT Instruments in order to integrate the latter company’s technology into the former company’s manufacturing process, with an aim to shorten the drug development timelines from clinical trials to market. Earlier, in April 2023, Microbiotica had signed an agreement with MSD to evaluate the clinical activity of its live biotherapeutic product, MB097, in combination with KEYTRUDA®, MSD’s anti-PD-1 therapy, in melanoma patients with primary resistance to an anti-PD-1-containing immunotherapy. This can be attributed to the incessant efforts of microbiome manufacturers to further advance the development of their product offerings, across different phases.

Microbiome Contract Manufacturing Companies’ Capacity Utilization Rate is Expected to Increase Significantly in the Coming Years

Around 43% of the global microbiome contract manufacturing capacity is installed in facilities owned by small contract manufacturing companies. Further, majority share (57%) of the overall microbiome manufacturing capacity is installed in facilities located in Europe; within Europe, more than 35% of this capacity is installed in facilities owned by players based in Austria. This can be attributed to the fact that majority of the manufacturing facility dedicated to the production of microbiome are located in Europe. It is worth mentioning that, over the past few years, the microbiome manufacturing capacity installed in Asia-Pacific and rest of the world has also increased at a commendable pace. This is primarily driven by the technical advances, low labor costs and socio-economic reforms favoring the growth of specialty industries, such as the microbiome industry.

Microbiome Manufacturing Market Size: Europe to Hold the Largest Market Share

The microbiome manufacturing market is estimated to be worth USD 27 million in 2023. Driven by the growing pipeline of microbiome-based products, the microbiome manufacturing market is anticipated to grow at a CAGR of 17% during the forecast period. Specifically, in terms of type of product manufactured, majority of the market share is anticipated to be captured by APIs by 2035. Further, the liquid dosage form continues to hold the largest share (50%) in the contract manufacturing industry.

Leading Contract Manufacturing Companies Engaged in Microbiome Manufacturing Market

Examples of key microbiome contract manufacturing companies (which have also been profiled in this report) offering manufacturing services include (in alphabetical order) Biose, BJP Laboratories, Capsugel, Cerbios-Pharma, Chr. Hansen, Inpac Probiotics, NIZO, WACKER and Winclove. In addition, MaaT Pharma is in the process of expanding its cGMP manufacturing capacity through the addition of a new plant in France that will exclusively focus on microbiome therapeutics manufacturing; the plant is set to be operational before the end of 2023. This market report includes an easily searchable excel database of all the microbiome contract manufacturing companies and their manufacturing facility, worldwide.

Recent Developments in Microbiome Manufacturing Market

Several recent developments have taken place in the field of microbiome manufacturing. These developments, even if they took place post the release of the market report, substantiate the overall market trends that have been outlined in the analyses. Some of the recent instances have been mentioned below.

  • In July 2023, MaaT Pharma joined Microbiome Therapeutics Innovation Group, a company leading the research and development of FDA-approved microbiome live biotherapeutics.
  • In March 2023, Mbiomics, a German-based microbiome company, raised USD 13 million in a series A round led by MIG Capital. The company plans to use the funds for the development of its proprietary platform, in order to accelerate the identification of the lead drug candidates and expedite the research towards clinical validation.

Scope of the Report

The study presents an in-depth analysis of the various firms / organizations that are engaged in microbiome manufacturing industry, across different segments, as defined below:

  • Base Year: 2022
  • Forecast Period: 2023-2035
  • Market Size 2023: $27 Million
  • CAGR: 17%
  • Customization Scope: 15% Customization Available
  • PowerPoint Presentation: (Complimentary)
  • Type of Product Manufactured
    • API
    • FDF
  • Type of Formulation
    • Solid
    • Liquid
    • Others
  • Type of Primary Packaging Used
    • Blister Packs
    • Glass / Plastic Bottles
    • Pouches / Sachets
    • Vials
  • Scale of Operation
    • Clinical
    • Commercial
  • Company Size
    • Small
    • Mid-sized
    • Large and Very Large
  • Key Geographical Regions
    • North America
    • Europe
    • Asia-Pacific
    • Rest of the World
  • Leading Developers
    • Infant Bacterial Therapeutics
    • MaaT Pharma
    • Microbiomik Healthcare
    • OxThera
    • Rebiotix
    • Seres Therapeutics
  • Key Companies Profiled
    • Biose
    • BJP Laboratories
    • Capsugel
    • Chr. Hansen
    • Inpac Probiotics
    • NIZO
    • WACKER
    • Winclove
    • (Full list of more than 60 companies captured is available in the report)
  • Excel Data Packs: (Complimentary)
    • Market Landscape Analysis
    • Company Competitiveness Analysis
    • Likely Partner Analysis
    • Big Pharma Initiatives
    • Recent Developments and Initiatives
    • Clinical Trial Analysis
    • Capacity Analysis
    • Demand Analysis
    • Market Forecast and Opportunity Analysis

The microbiome manufacturing market report presents an in-depth analysis, highlighting the capabilities of various companies engaged in this industry, across different geographies.

Amongst other elements, the market research report features:

  • A preface providing an introduction to the full report, Microbiome Manufacturing Market, 2023-2035.
  • An outline of the systematic research methodology adopted to conduct the study on microbiome manufacturing market, including live biotherapeutic products, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of the findings.
  • An overview of economic factors that impact the overall microbiome manufacturing industry, including historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
  • An executive summary of the key insights captured during the research, offering a high-level view on the current state of the microbiome manufacturing market and its likely evolution in the short to mid and long term.
  • A general overview of the concept of the human microbiota and microbiome, along with information on the various types of microbiome therapeutics. It also features an elaborate discussion on the functions of the microbiota, emphasizing on the key insights generated from the human microbiome project (HMP). Further, the chapter features the various steps that are involved in the manufacturing of microbiome therapeutics. In addition, it highlights the challenges associated with manufacturing such products and the growing need for outsourcing in this domain. Finally, it provides a list of key factors that need to be considered by innovator companies while selecting a CMO partner.
  • A overview of the current market landscape of companies engaged in offering microbiome manufacturing services for the development of microbiome therapeutics, along a detailed analysis based on several relevant parameters, such as year of establishment, company size, location of headquarters, scale of operation (preclinical, clinical and commercial, type of product manufactured (API and FDF), type of formulation (solids, liquids and other forms), type of primary packaging used (blister packs, sachets / pouches, glass / plastic bottles and vials), type of microbe used (aerobic, anaerobic and genetically engineered strains), type of service offered (strain isolation, lyophilization, fill-finish, cell banking, analytical services / quality control, process development), number and location of manufacturing facilities and bioprocessing capacity, type of microbial species used (Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, E.coli, Bacillus, Clostridium, Faecalibacterium, Others).
  • A detailed landscape of the microbiome manufacturing facilities established across key geographical regions (North America, Europe and Asia-Pacific), highlighting the key manufacturing hubs for microbiomes.
  • An in-depth company competitiveness analysis of microbiome manufacturing service providers based on supplier strength (in terms of years of experience), portfolio strength (in terms of scale of operation, type of product manufactured, type of formulation, type of primary packaging used and number of manufacturing facilities) and number of services offered.
  • Detailed profiles of the key players (large and mid-sized companies, established before 2000) based in North America, Europe and Asia-Pacific that offer contract manufacturing services for live biotherapeutic products at both clinical and commercial scales of operations. Each profile features a brief overview of the company, microbiome-related service portfolio, along with information on microbiome manufacturing facilities, and recent developments and an informed future outlook.
  • A list of nearly 70 microbiome-focused drug developers that are likely to partner with manufacturers engaged in this domain. These players have been shortlisted based on several relevant parameters, such as developer score (which takes into account the company’s size and its experience in this field), pipeline maturity (which takes into account the number of pipeline drugs and their affiliated stage of development), pipeline strength (which takes into account the number of microbiome drugs in the company’s pipeline), and availability of in-house manufacturing capabilities.
  • An analysis of the various microbiome-focused initiatives undertaken by big pharma players (shortlisted based on the revenues generated by the top 15 pharmaceutical companies in 2022) featuring heat map representations of these players highlighting their initiatives (in terms of partnerships, funding and investments, early stage pipeline, late stage pipeline, therapeutic areas and portfolio diversity), and a spider web representation comparing the initiatives of big pharma players based on several relevant parameters.
  • An analysis of recent developments in the microbiome manufacturing industry, featuring information on several partnerships and collaborations, mergers and acquisitions, and expansion initiatives that have taken place in this domain, during the period 2016-2023.
  • An in-depth analysis of completed, ongoing, and planned clinical studies of various microbiome therapeutics, based on several relevant parameters, such as trial registration year, trial status, trial phase, enrolled patient population, type of sponsor, most active industry players (in terms of number of trials conducted), study design, therapeutic area and key geographical regions.
  • An estimate of the overall installed capacity for manufacturing of microbiome-based therapies, based on information reported by various industry stakeholders in the public domain, highlighting the distribution of the available capacity based on the company size (small, mid-sized, and large and very large firms) and key geographical regions (North America, Europe, Asia-Pacific and Rest of the World).
  • An informed estimate of the annual clinical and commercial demand for microbiome therapeutics, taking into account the target patient population in ongoing and planned clinical trials of microbiome therapeutics, sponsored by both industry and non-industry players.
  • A qualitative analysis, highlighting various factors that need to be taken into consideration by microbiome therapeutics developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
  • A case study on the current market landscape of microbiome contract research organizations and dietary supplement providers, including information on their year of establishment, company size and location of headquarters.

The key objective of this market report is to provide a detailed market forecast analysis in order to estimate the existing microbiome manufacturing market size and future opportunity for microbiome manufacturers over the next decade. Based on several parameters, likely adoption trends and through primary validations, the analyst has provided an informed estimate on the market evolution during the forecast period 2023-2035. The market report also features the likely distribution of the current and forecasted opportunity within the microbiome manufacturing market across various relevant parameters, such as distribution by type of product manufactured (API and FDF), type of formulation (solid, liquid and others), type of primary packaging used (blister packs, glass / plastic bottles, pouches / sachets and vials), scale of operation (clinical and commercial), company size (small, mid-sized, and large and very large), key geographical regions (North America, Europe, Asia-Pacific, and Rest of the World) and leading developers. In order to account for future uncertainties with some of the key parameters and add robustness to the model, the analyst has provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in the market report were influenced by discussions held with stakeholders in the industry:

  • Founder and Executive Chairman, Small Company, US
  • Managing Director and Scientific Head, Large Company, India
  • Managing Director and Chief Executive Officer, Mid-sized Company, India
  • Co-Founder and Chief Executive Officer, Small Company, Belgium
  • Founder and Chief Executive Officer, Small Company, US
  • Chief Business Officer, Mid-sized Company, Israel
  • Chief Operating Officer, Mid-sized Company, US
  • Vice President, Business Development, Small Company, US
  • Vice President, Commercial Operations, Mid-sized Company, US
  • Vice President, Business Development, Mid-sized Company, US
  • Vice President, Sales and Business Development, Small Company, US
  • Head of Business Development, Mid-sized Company, Australia
  • Business Development Manager, Large Company, Germany

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.

Table of Contents

1. PREFACE
1.1. Live Biotherapeutic Products and Microbiome Manufacturing Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Inclusions and Exclusions
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Future Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
4.1. Chapter Overview
5. INTRODUCTION
5.1. Chapter Overview
5.2. Concept of Human Microbiota and Microbiome
5.3. Overview of Gut Flora
5.3.1. Role of Gut Flora in Healthy Individuals
5.3.2. Factors Affecting Human Gut Flora
5.4. The Human Microbiome Project (HMP)
5.5. Overview of Microbiome Therapies
5.5.1. Types of Microbiome Therapies
5.5.1.1. Probiotics
5.5.1.2. Prebiotics
5.5.2. Applications of Microbiome Therapies
5.5.3. Microbiome Therapies Supply Chain
5.6. Manufacturing of Microbiome-based Therapeutics
5.6.1. Key Steps Involved
5.6.2. Challenges Associated with Manufacturing of Microbiome Therapeutics
5.6.3. Demand for Contract Manufacturing Services
5.7. Key Considerations while Selecting a Suitable CMO Partner
5.8. Concluding Remarks
6. MARKET LANDSCAPE
6.1. Chapter Overview
6.2. Live Biotherapeutic Products and Microbiome Contract Manufacturers: Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by Scale of Operation
6.2.5. Analysis by Type of Product Manufactured
6.2.6. Analysis by Type of Formulation
6.2.7. Analysis by Scale of Operation and Type of Formulation
6.2.8. Analysis by Type of Primary Packaging Used
6.2.9. Analysis by Type of Formulation and Type of Primary Packaging Used
6.2.10. Analysis by Type of Microbe Used
6.2.11. Analysis by Type of Microbe Used and Location of Headquarters
6.2.12. Analysis by Type of Service Offered
6.2.13. Analysis by Number of Manufacturing Facilities (Region)
6.2.14. Analysis by Number of Manufacturing Facilities (Country)
6.2.15. Analysis by Type of Microbial Species Used
6.3. Live Biotherapeutic Products and Microbiome In-House Manufacturers: Market Landscape
6.3.1. Analysis by Year of Establishment
6.3.2. Analysis by Company Size
6.3.3. Analysis by Location of Headquarters
6.3.4. Analysis by Scale of Operation
6.3.5. Analysis by Location of Manufacturing Facilities
7. REGIONAL CAPABILITY ANALYSIS
7.1. Chapter Overview
7.2. Key Assumptions and Parameters
7.3. Live Biotherapeutic Products and Microbiome Contract Manufacturers in North America
7.4. Live Biotherapeutic Products and Microbiome Contract Manufacturers in Europe
7.5. Live Biotherapeutic Products and Microbiome Contract Manufacturers in Asia-Pacific
8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Key Assumptions and Parameters
8.3. Methodology
8.4. Live Biotherapeutic Products and Microbiome Contract Manufacturers: Company Competitiveness Analysis:
8.5. Capability Benchmarking of Top Microbiome Contract Manufactures
9. COMPANY PROFILES
9.1. Chapter Overview
9.2. Leading Live Biotherapeutic Products and Microbiome Contract Manufacturers in North America
9.2.1. Capsugel (Acquired by Lonza)
9.2.1.1. Company Overview
9.2.1.2. Service Portfolio
9.2.1.3. Facilities Dedicated to Microbiome Manufacturing
9.2.1.4. Recent Developments and Future Outlook
9.3. Other Prominent Live Biotherapeutic Products and Microbiome Contract Manufacturers in North America
9.3.1. Arranta Bio
9.3.1.1. Company Overview
9.3.1.2. Service Portfolio
9.3.2. FUJIFILM Diosynth Biotechnologies
9.3.2.1. Company Overview
9.3.2.2. Service Portfolio
9.3.3. List Biological Laboratories
9.3.3.1. Company Overview
9.3.3.2. Service Portfolio
9.3.4. ProbioFerm
9.3.4.1. Company Overview
9.3.4.2. Service Portfolio
9.4. Leading Live Biotherapeutic Products and Microbiome Contract Manufacturers in Europe
9.4.1. Biose Industrie
9.4.1.1. Company Overview
9.4.1.2. Service Portfolio
9.4.1.3. Facilities Dedicated to Microbiome Manufacturing
9.4.1.4. Recent Developments and Future Outlook
9.4.2. Cerbios-Pharma
9.4.2.1. Company Overview
9.4.2.2. Service Portfolio
9.4.2.3. Facilities Dedicated to Microbiome Manufacturing
9.4.2.4. Recent Developments and Future Outlook
9.4.3. Chr. Hansen
9.4.3.1. Company Overview
9.4.3.2. Financial Information
9.4.3.3. Service Portfolio
9.4.3.4. Facilities Dedicated to Microbiome Manufacturing
9.4.3.5. Recent Developments and Future Outlook
9.4.4. Inpac Probiotics
9.4.4.1. Company Overview
9.4.4.2. Service Portfolio
9.4.4.3. Facilities Dedicated to Microbiome Manufacturing
9.4.4.4. Recent Developments and Future Outlook
9.4.5. NIZO
9.4.5.1. Company Overview
9.4.5.2. Service Portfolio
9.4.5.3. Facilities Dedicated to Microbiome Manufacturing
9.4.5.4. Recent Developments and Future Outlook
9.4.6. WACKER
9.4.6.1. Company Overview
9.4.6.2. Service Portfolio
9.4.6.3. Facilities Dedicated to Microbiome Manufacturing
9.4.6.4. Recent Developments and Future Outlook
9.4.7 Winclove Probiotics
9.4.7.1. Company Overview
9.4.7.2. Service Portfolio
9.4.7.3. Facilities Dedicated to Microbiome Manufacturing
9.4.7.4. Recent Developments and Future Outlook
9.5. Other Prominent Live Biotherapeutic Products and Microbiome Contract Manufacturers in Europe
9.5.1. BacThera
9.5.1.1. Company Overview
9.5.1.2. Service Portfolio
9.5.2. Evologic Technologies
9.5.2.1 Company Overview
9.5.2.2. Service Portfolio
9.5.3. Probiotical
9.5.3.1. Company Overview
9.5.3.2. Service Portfolio
9.5.4. QUAY Pharma
9.5.4.1. Company Overview
9.5.4.2. Service Portfolio
9.6. Leading Live Biotherapeutic Products and Microbiome Contract Manufacturers in Asia-Pacific
9.6.1. BJP Laboratories
9.6.1.1. Company Overview
9.6.1.2. Service Portfolio
9.6.1.3. Facilities Dedicated to Microbiome Manufacturing
9.6.1.4. Recent Developments and Future Outlook
9.7. Other Prominent Live Biotherapeutic Products and Microbiome Contract Manufacturers in Asia-Pacific
9.7.1. Aumgene Biosciences
9.7.1.1 Company Overview
9.7.1.2. Service Portfolio
9.7.2. AcuraBio
9.7.2.1. Company Overview
9.7.2.2. Service Portfolio
9.7.3. Meteoric Biopharmaceuticals
9.7.3.1. Company Overview
9.7.3.2. Service Portfolio
9.7.4. Probiotics Australia
9.7.4.1. Company Overview
9.7.4.2. Service Portfolio
9.7.5. Unique Biotech
9.7.5.1 Company Overview
9.7.5.2. Service Portfolio
10. LIKELY PARTNER ANALYSIS
10.1. Chapter Overview
10.2. Key Assumptions and Key Parameters
10.3. Scope and Methodology
10.4. Key Potential Strategic Partners for Live Biotherapeutic Products and Microbiome Contract Manufacturers
10.4.1. Likely Partners in North America
10.4.2. Likely Partners in Europe
10.4.3. Likely Partners in Asia-Pacific
11. BIG PHARMA INITIATIVES
11.1. Chapter Overview
11.2. Methodology
11.3. Live Biotherapeutic Products and Microbiome-related Initiatives of Big Pharmaceutical Players
11.3.1. Analysis by Portfolio Diversity
11.3.2. Analysis by Trial Phase
11.3.3. Analysis by Type of Therapy
11.3.4. Analysis by Type of Molecule
11.3.5. Analysis by Therapeutic Area
12. RECENT DEVELOPMENTS AND INITIATIVES
12.1. Chapter Overview
12.2. Partnerships and Collaborations
12.2.1. Partnership Models
12.2.2. Live Biotherapeutic Products and Microbiome Manufacturing: List of Partnerships and Collaborations
12.2.3. Analysis by Year of Partnership
12.2.4. Analysis by Type of Partnership
12.2.5. Analysis by Year and Type of Partnership
12.2.6. Analysis by Type of Organization
12.2.7. Analysis by Type of Partnership and Type of Organization
12.2.8. Analysis by Therapeutic Area
12.2.9. Most Active Players: Analysis by Number of Partnerships
12.2.10. Analysis by Geography
12.2.10.1. Intracontinental and Intercontinental Agreements
12.2.10.2. Local and International Agreements
12.3. Live Biotherapeutic Products and Microbiome Manufacturing: Mergers and Acquisitions
12.3.1. Cumulative Year-wise Trend of Merger / Acquisition
12.3.2. Analysis by Key Value Drivers
12.3.3. Analysis by Year of Acquisition and Key Value Drivers
12.4. Live Biotherapeutic Products and Microbiome Manufacturing: Recent Expansions
12.4.1. Analysis by Year of Expansion
12.4.2. Analysis by Purpose of Expansion
12.4.3. Analysis by Year and Purpose of Expansion
12.4.4. Analysis by Scale of Operation
12.4.5. Analysis by Purpose of Expansion and Scale of Operation
12.4.6. Analysis by Geography
12.4.6.1. Analysis by Location of Expanded Facility (Region)
12.4.6.2. Analysis by Location of Expanded Facility (Country)
12.4.7. Analysis by Purpose of Expansion and Location of Expanded Facility (Region)
13. CLINICAL TRIAL ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Live Biotherapeutic Products and Microbiome Manufacturing: Clinical Trial Analysis
13.3.1. Analysis by Trial Registration Year
13.3.2. Analysis by Trial Status
13.3.3. Analysis by Trial Registration Year and Trial Status
13.3.4. Analysis by Trial Phase
13.3.5. Analysis by Trial Registration Year and Trial Phase
13.3.6. Analysis of Enrolled Patient Population by Trial Registration Year
13.3.7. Analysis of Enrolled Patient Population by Trial Phase
13.3.8. Analysis by Type of Sponsor
13.3.9. Most Active Players: Analysis by Number of Registered Trials
13.3.10. Analysis by Study Design
13.3.11. Analysis by Therapeutic Area
13.3.12. Analysis of Number of Registered Trials by Geography
13.3.13. Analysis of Number of Registered Trials by Trial Status and Geography
13.3.14. Analysis of Enrolled Patient Population by Geography
13.3.15. Analysis of Enrolled Patient Population by Trial Status and Geography
14. CAPACITY ANALYSIS
14.1. Chapter Overview
14.2. Key Assumptions
14.3. Live Biotherapeutic Products and Microbiome Contract Manufacturing: Global Installed Capacity
14.3.1. Analysis by Company Size
14.3.2. Analysis by Geography
14.3.2.1. Analysis of Installed Live Biotherapeutic Products and Microbiome Contract Manufacturing Capacity in North America
14.3.2.2. Analysis of Installed Live Biotherapeutic Products and Microbiome Contract Manufacturing Capacity in Europe
14.3.2.3. Analysis of Installed Live Biotherapeutic Products and Microbiome Contract Manufacturing Capacity Asia-Pacific and Rest of the World
15. DEMAND ANALYSIS
15.1. Chapter Overview
15.2. Methodology
15.3. Global Clinical Demand for Live Biotherapeutic Products and Microbiome Manufacturing
15.3.1. Analysis by Number of Trials Conducted
15.3.2. Analysis by Enrolled Patient Population
15.3.3. Analysis by Trial Phase
15.3.4. Analysis by Geography
15.3.4.1. Clinical Demand in North America
15.3.4.2. Clinical Demand in Europe
15.3.4.3. Clinical Demand in Asia-Pacific and Rest of the World
15.4. Global Commercial Demand for Live Biotherapeutic Products and Microbiome Manufacturing
16. MAKE VERSUS BUY DECISION MAKING FRAMEWORK
16.1. Chapter Overview
16.2. Key Assumptions and Parameters
16.3. Live Biotherapeutic Products and Microbiome Contract Manufacturers: Make versus Buy Decision Making Framework
16.3.1. Scenario 1
16.3.2. Scenario 2
16.3.3. Scenario 3
16.3.4. Scenario 4
16.4. Concluding Remarks
17. CASE STUDY: LIVE BIOTHERAPEUTIC PRODUCTS AND MICROBIOME CONTRACT RESEARCH ORGANIZATIONS (CROs) AND DIETARY SUPPLEMENT MANUFACTURERS
17.1 Chapter Overview
17.2. Live Biotherapeutic Products and Microbiome CROs
17.3. Live Biotherapeutic Products and Microbiome CROs: Market Landscape
17.3.1. Analysis by Year of Establishment
17.3.2. Analysis by Company Size
17.3.3. Analysis by Location of Headquarters
17.4. Microbiome Dietary Supplement Manufacturers: Market Landscape
17.4.1. Analysis by Year of Establishment
17.4.2. Analysis by Company Size
17.4.3. Analysis by Location of Headquarters
18. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
18.1. Chapter Overview
18.2. Market Drivers
18.3. Market Restraints
18.4. Market Opportunities
18.5. Market Challenges
18.6. Conclusion
19. LIVE BIOTHERAPEUTIC PRODUCTS AND MICROBIOME CONTRACT MANUFACTURING MARKET
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Global Live Biotherapeutic Products and Microbiome Contract Manufacturing Market, 2023-2035
19.4. Scenario Analysis
19.4.1. Conservative Scenario
19.4.2. Optimistic Scenario
19.5. Key Market Segmentations
20. LIVE BIOTHERAPEUTIC PRODUCTS AND MICROBIOME CONTRACT MANUFACTURING MARKET, BY TYPE OF PRODUCT MANUFACTURED
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Distribution by Type of Product Manufactured, 2023 and 2035
20.3.1. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for API, 2023-2035
20.3.2. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for FDF, 2023-2035
20.4. Data Triangulation
21. LIVE BIOTHERAPEUTIC PRODUCTS AND MICROBIOME CONTRACT MANUFACTURING MARKET, BY TYPE OF FORMULATION
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Distribution by Type of Formulation, 2023 and 2035
21.3.1. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Solids, 2023-2035
21.3.2. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Liquids, 2023-2035
21.3.3. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Others, 2023-2035
21.4. Data Triangulation
22. LIVE BIOTHERAPEUTIC PRODUCTS AND MICROBIOME CONTRACT MANUFACTURING MARKET, BY TYPE OF PRIMARY PACKAGING USED
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Distribution by Type of Primary Packaging Used, 2023 and 2035
22.3.1. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Blister Packs, 2023-2035
22.3.2. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Glass / Plastic Bottles, 2023-2035
22.3.3. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Sachets / Pouches, 2023-2035
22.3.4. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Vials, 2023-2035
22.4. Data Triangulation
23. LIVE BIOTHERAPEUTIC PRODUCTS AND MICROBIOME CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Distribution by Scale of Operation, 2023 and 2035
23.3.1. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Clinical, 2023-2035
23.3.2. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Commercial, 2023-2035
23.4. Data Triangulation
24. LIVE BIOTHERAPEUTIC PRODUCTS AND MICROBIOME CONTRACT MANUFACTURING MARKET, BY COMPANY SIZE
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Distribution by Company Size, 2023 and 2035
24.3.1. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Small Companies, 2023-2035
24.3.2. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Mid-sized Companies, 2023-2035
24.3.3. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Large and Very Large Companies, 2023-2035
24.4. Data Triangulation
25. LIVE BIOTHERAPEUTIC PRODUCTS AND MICROBIOME CONTRACT MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS
25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Distribution by Key Geographical Regions, 2023 and 2035
25.3.1. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market in North America, 2023-2035
25.3.2. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market in Europe, 2023-2035
25.3.3. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market in Asia-Pacific, 2023-2035
25.3.4. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market in Rest of the World, 2023-2035
25.4. Data Triangulation
26. LEADING DEVELOPERS FOR LIVE BIOTHERAPEUTIC PRODUCTS AND MICROBIOME THERAPIES
26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3. Live Biotherapeutic Products and Microbiome Therapeutics Market: Distribution by Leading Developers
26.4. Data Triangulation
27. EXECUTIVE INSIGHTS
27.1. Chapter Overview
27.2. Osel
27.2.1. Company Snapshot
27.2.2. Interview Transcript: Peter P. Lee, Founder and Executive Chairman
27.3. Unique Biotech
27.3.1. Company Snapshot
27.3.2. Interview Transcript: Ratna Sudha and Jayanthi, Managing Director and Scientific Head
27.4. Meteoric Biopharmaceuticals
27.4.1. Company Snapshot
27.4.2. Interview Transcript: Gaurav Kaushik, Managing Director and Chief Executive Officer
27.5. Biomedic
27.5.1. Company Snapshot
27.5.2. Interview Transcript: Veronika Oudova, Co- Founder and Chief Executive Officer
27.6. Siolta Therapeutics
27.6.1. Company Snapshot
27.6.2. Interview Transcript: Nikole Kimes, Founder and Chief Executive Officer
27.7. BiomX
27.7.1. Company Snapshot
27.8.2. Interview Transcript: Assaf Oron, Chief Business Officer
27.8. Vedanta Biosciences
27.8.1. Company Snapshot
27.8.2. Interview Transcript: Daniel Couto, Chief Operating Officer
27.9. Universal Stabilization Technologies
27.9.1. Company Snapshot
27.9.2. Interview Transcript: Alexander Segal, Former Vice President, Business Development
\27.10. Arranta Bio
27.10.1. Company Snapshot
27.10.2. Interview Transcript: Traci Kyes, Former Vice President, Commercial Operations
27.11. Assembly Biosciences
27.11.1. Company Snapshot
27.11.2. Interview Transcript: JP Benya, Former Vice President, Business Development
27.12. List Biological Laboratories
27.12.1. Company Snapshot
27.12.2. Interview Transcript: Debbie Pinkston, Former Vice President. Sales and Business Development
27.13. Luina Bio
27.13.1. Company Snapshot
27.13.2. Interview Transcript: Max Rosetto, Head of Business Development
27.14. WACKER
27.14.1. Company Snapshot
27.14.2. Interview Transcript: Rob Van Dijk, Business Development Manager
28. CONCLUDING REMARKS29. APPENDIX I: TABULATED DATA30. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
LIST OF FIGURES
Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Forecast Methodology
Figure 2.3 Research Methodology: Robust Quality Control
Figure 2.4 Research Methodology: Key Market Segmentations
Figure 4.1 Executive Summary: CMOs Market Landscape
Figure 4.2 Executive Summary: In-house Manufacturers Market Landscape
Figure 4.3 Executive Summary: Recent Developments and Initiatives
Figure 4.4 Executive Summary: Clinical Trial Analysis
Figure 4.5 Executive Summary: Capacity Analysis
Figure 4.6 Executive Summary: Demand Analysis
Figure 4.7 Executive Summary: Market Sizing and Opportunity Analysis
Figure 5.1 Key Benefits of Human Microbiota
Figure 5.2 Factors Affecting the Gut Flora
Figure 5.3 Human Microbiome Project: Key Achievements
Figure 5.4 Types of Microbiome Therapies
Figure 5.5 Probiotic Drugs: Overview of Beneficial Bacterial Strains
Figure 5.6 Microbiome Therapies: Potential Application Areas
Figure 5.7 Key Steps Involved in Microbiome Therapeutics Supply Chain
Figure 5.8 Key Steps Involved in Microbiome Therapeutics Manufacturing
Figure 5.9 Key Challenges in Manufacturing of Microbiome Therapeutics
Figure 5.10 Key Strategies to Increase Efficiency in Manufacturing Microbiome Therapeutics
Figure 6.1 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Year of Establishment
Figure 6.2 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Company Size
Figure 6.3 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Location of Headquarters
Figure 6.4 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Scale of Operation
Figure 6.5 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Product Manufactured
Figure 6.6 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Formulation
Figure 6.7 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Scale of Operation and Type of Formulation
Figure 6.8 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Primary Packaging Used
Figure 6.9 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Formulation and Type of Primary Packaging Used
Figure 6.10 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Microbe Used
Figure 6.11 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Microbe Used and Location of Headquarters
Figure 6.12 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Service Offered
Figure 6.13 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Number of Manufacturing Facilities (Region)
Figure 6.14 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Number of Manufacturing Facilities (Country)
Figure 6.15 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Microbial Species Used
Figure 6.16 Live Biotherapeutic Products and Microbiome In-House Manufacturers: Distribution by Year of Establishment
Figure 6.17 Live Biotherapeutic Products and Microbiome In-House Manufacturers: Distribution by Company Size
Figure 6.18 Live Biotherapeutic Products and Microbiome In-House Manufacturers: Distribution by Location of Headquarters
Figure 6.19 Live Biotherapeutic Products and Microbiome In-House Manufacturers: Distribution by Scale of Operation
Figure 6.20 Live Biotherapeutic Products and Microbiome In-House Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 7.1 Regional Capability Analysis: Live Biotherapeutic Products and Microbiome Contract Manufacturers in North America
Figure 7.2 Regional Capability Analysis: Live Biotherapeutic Products and Microbiome Contract Manufacturers in Europe
Figure 7.3 Regional Capability Analysis: Live Biotherapeutic Products and Microbiome Contract Manufacturers in Asia-Pacific
Figure 8.1 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Company Competitiveness Analysis
Figure 8.2 Benchmarking Analysis: Distribution of Top Live Biotherapeutic Products and Microbiome Contract Manufacturers
Figure 9.1 Capsugel: Service Portfolio
Figure 9.2 Biose Industrie: Service Portfolio
Figure 9.3 Cerbios-Pharma: Service Portfolio
Figure 9.4 Chr. Hansen: Service Portfolio
Figure 9.5 Inpac Probiotics: Service Portfolio
Figure 9.6 NIZO: Service Portfolio
Figure 9.7 WACKER: Service Portfolio
Figure 9.8 Winclove Probiotics: Service Portfolio
Figure 9.9 BJP Laboratories: Service Portfolio
Figure 11.1 Live Biotherapeutic Products and Microbiome Related Initiatives: Spider Web Analysis of Top Big Pharma Players
Figure 11.2 Big Pharma Players: Distribution by Portfolio Diversity
Figure 11.3 Big Pharma Players: Distribution by Trial Phase
Figure 11.4 Big Pharma Players: Distribution by Type of Therapy
Figure 11.5 Big Pharma Players: Distribution by Type of Molecule
Figure 11.6 Big Pharma Players: Distribution by Therapeutic Area
Figure 12.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 12.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 12.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 12.4 Partnerships and Collaborations: Distribution by Type of Organization
Figure 12.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Organization
Figure 12.6 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 12.7 Most Active Players: Distribution by Number of Partnerships
Figure 12.8 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Figure 12.9 Partnerships and Collaborations: Local and International Agreement
Figure 12.10 Mergers and Acquisitions: Cumulative Year-wise Trend, 2016-2023
Figure 12.11 Mergers and Acquisitions: Distribution by Key Value Drivers
Figure 12.12 Mergers and Acquisitions: Distribution by Year of Mergers and Acquisitions and Key Value Driver
Figure 12.13 Recent Expansions: Distribution by Year of Expansion
Figure 12.14 Recent Expansions: Distribution by Purpose of Expansion
Figure 12.15 Recent Expansions: Distribution by Year and Purpose of Expansion
Figure 12.16 Recent Expansions: Distribution by Scale of Operation
Figure 12.17 Recent Expansions: Distribution by Purpose of Expansion and Scale of Operation
Figure 12.18 Recent Expansions: Distribution by Location of Expanded Facility (Region)
Figure 12.19 Recent Expansions: Distribution by Location of Expanded Facility (Country)
Figure 12.20 Recent Expansions: Distribution by Purpose of Expansion and Location of Expanded Facility (Region)
Figure 13.1 Clinical Trial Analysis: Scope and Methodology
Figure 13.2 Clinical Trial Analysis: Distribution by Trial Registration Year, Pre-2015-2023
Figure 13.3 Clinical Trial Analysis: Distribution by Trial Status
Figure 13.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2015-2023
Figure 13.5 Clinical Trial Analysis: Distribution by Trial Phase
Figure 13.6 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, Pre-2019-2023
Figure 13.7 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, Pre-2015-2023
Figure 13.8 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 13.9 Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 13.10 Most Active Players: Distribution by Number of Registered Trials
Figure 13.11 Clinical Trial Analysis: Distribution by Study Design
Figure 13.12 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 13.13 Clinical Trial Analysis: Distribution of Number of Registered Trials by Geography
Figure 13.14 Clinical Trial Analysis: Distribution of Number of Registered Trials by Trial Status and Geography
Figure 13.15 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Figure 13.16 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status and Geography
Figure 14.1 Global Installed Live Biotherapeutic Products and Microbiome Contract Manufacturing Capacity: Distribution by Company Size
Figure 14.2 Global Installed Live Biotherapeutic Products and Microbiome Contract Manufacturing Capacity: Distribution by Geography
Figure 14.3 Global Installed Live Biotherapeutic Products and Microbiome Contract Manufacturing Capacity in North America
Figure 14.4 Global Installed Live Biotherapeutic Products and Microbiome Contract Manufacturing Capacity in Europe
Figure 14.5 Global Installed Live Biotherapeutic Products and Microbiome Contract Manufacturing Capacity in Asia-Pacific and Rest of the World
Figure 15.1 Global Demand for Live Biotherapeutic Products and Microbiome Manufacturing, 2023-2035: Distribution by Number of Trials Conducted
Figure 15.2 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Manufacturing, 2023-2035: Distribution by Enrolled Patient Population
Figure 15.3 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Manufacturing, 2023-2035: Distribution by Trial Phase
Figure 15.4 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Manufacturing: Distribution by Geography
Figure 15.5 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Manufacturing in North America, 2023-2035
Figure 15.6 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Manufacturing in Europe, 2023-2035
Figure 15.7 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Manufacturing in Asia-Pacific and Rest of the World, 2023-2035
Figure 15.8 Global Commercial Demand for Live Biotherapeutic Products and Microbiome Manufacturing, 2023-2035: Distribution by Number of Target Patient Population (in Million)
Figure 15.9 Global Commercial Demand for Live Biotherapeutic Products and Microbiome Manufacturing, 2023-2035 (in cfu)
Figure 16.1 Make versus Buy Decision Making Framework
Figure 16.2 Make versus Buy Decision Making: Possible Scenario Descriptions
Figure 17.1 Live Biotherapeutic Products and Microbiome CROs: Distribution by Year of Establishment
Figure 17.2 Live Biotherapeutic Products and Microbiome CROs: Distribution by Company Size
Figure 17.3 Live Biotherapeutic Products and Microbiome CROs: Distribution by Location of Headquarters
Figure 17.4 Microbiome Dietary Supplement Manufacturers: Distribution by Year of Establishment
Figure 17.5 Microbiome Dietary Supplement Manufacturers: Distribution by Company Size
Figure 17.6 Microbiome Dietary Supplement Manufacturers: Distribution by Location of Headquarters
Figure 18.1 Live Biotherapeutic Products and Microbiome Contract Manufacturing: Market Drivers
Figure 18.2 Live Biotherapeutic Products and Microbiome Contract Manufacturing: Market Restraints
Figure 18.3 Live Biotherapeutic Products and Microbiome Contract Manufacturing: Market Opportunities
Figure 18.4 Live Biotherapeutic Products and Microbiome Contract Manufacturing: Market Challenges
Figure 19.1 Global Live Biotherapeutic Products and Microbiome Contract Manufacturing Market, 2023-2035: Base Scenario (USD Million)
Figure 19.2 Global Live Biotherapeutic Products and Microbiome Contract Manufacturing Market, 2023-2035: Conservative Scenario (USD Million)
Figure 19.3 Global Live Biotherapeutic Products and Microbiome Contract Manufacturing Market, 2023-2035: Optimistic Scenario (USD Million)
Figure 20.1 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Distribution by Type of Product Manufactured, 2023 and 2035
Figure 20.2 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for API, 2023-2035 (USD Million)
Figure 20.3 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for FDF, 2023-2035 (USD Million)
Figure 21.1 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Distribution by Type of Formulation, 2023 and 2035
Figure 21.2 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Solids, 2023-2035 (USD Million)
Figure 21.3 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Liquids, 2023-2035 (USD Million)
Figure 21.4 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Others, 2023-2035 (USD Million)
Figure 22.1 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Distribution by Type of Primary Packaging Used, 2023 and 2035
Figure 22.2 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Blister Packs, 2023-2035 (USD Million)
Figure 22.3 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Glass / Plastic Bottles, 2023-2035 (USD Million)
Figure 22.4 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Sachets / Pouches, 2023-2035 (USD Million)
Figure 22.5 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Vials, 2023-2035 (USD Million)
Figure 23.1 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Distribution by Scale of Operation, 2023 and 2035
Figure 23.2 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Clinical, 2023-2035 (USD Million)
Figure 23.3 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Commercial, 2023-2035 (USD Million)
Figure 24.1 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Distribution by Company Size, 2023 and 2035
Figure 24.2 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Small Companies, 2023-2035 (USD Million)
Figure 24.3 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Mid-sized Companies, 2023-2035 (USD Million)
Figure 24.4 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Large and Very Large Companies, 2023-2035 (USD Million)
Figure 25.1 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Distribution by Key Geographical Regions, 2023 and 2035
Figure 25.2 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market in North America, 2023-2035 (USD Million)
Figure 25.3 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market in Europe, 2023-2035 (USD Million)
Figure 25.4 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market in Asia-Pacific, 2023-2035 (USD Million)
Figure 25.5 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market in Rest of the World, 2023-2035 (USD Million)
Figure 26.1 Live Biotherapeutic Products and Microbiome Therapeutics Market, Distribution by Leading Developers, 2035
Figure 28.1 Concluding Remarks: Overall Market Landscape
Figure 28.2 Concluding Remarks: Recent Developments and Initiatives
Figure 28.3 Concluding Remarks: Clinical Trial Analysis
Figure 28.4 Concluding Remarks: Capacity Analysis
Figure 28.5 Concluding Remarks: Demand Analysis
Figure 28.6 Concluding Remarks: Market Sizing and Opportunity Analysis (I/II)
Figure 28.7 Concluding Remarks: Market Sizing and Opportunity Analysis (II/II)
LIST OF TABLES
Table 5.1 Different Types of Microbiota in the Gastrointestinal Tract
Table 5.2 Various Food Items Containing Prebiotics
Table 5.3 Harvey Ball Analysis: Comparison of Key Factors for the Selection of CMOs
Table 6.1 List of Live Biotherapeutic Products and Microbiome Contract Manufacturers: Market Landscape
Table 6.2 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Information on Type of Product Manufactured
Table 6.3 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Information on Type of Formulation
Table 6.4 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Information on Type of Primary Packaging Used
Table 6.5 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Information on Type of Microbe Used
Table 6.6 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Information on Type of Service Offered
Table 6.7 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Information on Manufacturing Facilities
Table 6.8 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Information on Type of Microbial Species Used
Table 6.9 List of Live Biotherapeutic Products and Microbiome In-House Manufacturers: Market Landscape
Table 7.1 List of Live Biotherapeutic Products and Microbiome Contract Manufacturers in North America
Table 7.2 List of Live Biotherapeutic Products and Microbiome Contract Manufacturers in Europe
Table 7.3 List of Live Biotherapeutic Products and Microbiome Contract Manufacturers in Asia-Pacific
Table 9.1 Capsugel: Company Overview
Table 9.2. Arranta Bio: Company Overview
Table 9.3. FUJIFILM Diosynth Biotechnologies: Company Overview
Table 9.4 List Biological Laboratories: Company Overview
Table 9.5 ProbioFerm: Company Overview
Table 9.6 Biose: Company Overview
Table 9.7 Biose: Recent Developments and Future Outlook
Table 9.8 Cerbios-Pharma: Company Overview
Table 9.9 Cerbios Pharma: Recent Developments and Future Outlook
Table 9.10 Chr. Hansen: Company Overview
Table 9.11 Chr Hansen: Recent Developments and Future Outlook
Table 9.12 Inpac Probiotics: Company Overview
Table 9.13 Inpac Probiotics: Recent Developments and Future Outlook
Table 9.14 NIZO: Company Overview
Table 9.15 NIZO: Recent Developments and Future Outlook
Table 9.16 WACKER: Company Overview
Table 9.17 WACKER: Recent Developments and Future Outlook
Table 9.18 Winclove Probiotics: Company Overview
Table 9.19 Winclove Probiotics: Recent Developments and Future Outlook
Table 9.20 BacThera: Company Overview
Table 9.21 Evologic Technologies: Company Overview
Table 9.22 Probiotical: Company Overview
Table 9.23 QUAY Pharma: Company Overview
Table 9.24 BJP Laboratories: Company Overview
Table 9.25 BJP Laboratories: Recent Developments and Future Outlook
Table 9.26 Aumgene Biosciences: Company Overview
Table 9.27 AcuraBio: Company Overview
Table 9.28 Meteoric Biopharmaceuticals: Company Overview
Table 9.29 Probiotics Australia: Company Overview
Table 9.30: Unique Biotech: Company Overview
Table 10.1 Likely Partners for Live Biotherapeutic Products and Microbiome Contract Manufacturers in North America
Table 10.2 Likely Partners for Live Biotherapeutic Products and Microbiome Contract Manufacturers in Europe
Table 10.3 Likely Partners for Live Biotherapeutic Products and Microbiome Contract Manufacturers in Asia-Pacific
Table 12.1 Live Biotherapeutic Products and Microbiome Manufacturing: List of Partnerships and Collaborations, 2016-2023
Table 12.2 Partnerships and Collaborations: Information on Type of Agreement, 2016-2023
Table 12.3 Mergers and Acquisitions: Information on Key Value Drivers, 2016-2022
Table 12.4 Live Biotherapeutic Products and Microbiome Manufacturing: List of Recent Expansions, 2019-2023
Table 14.1 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Information on Total Capacity (Sample Data Set)
Table 14.2 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Average Capacity by Company Size (Sample Data Set)
Table 15.1 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Manufacturing: Information on Number of Enrolled Patients and Trial Phase
Table 15.2 Global Commercial Demand for Live Biotherapeutic Products and Microbiome Manufacturing: List of Microbiome-based Live Biotherapeutic Products
Table 17.1 List of Live Biotherapeutic Products and Microbiome CROs: Market Landscape
Table 17.2 Microbiome Dietary Supplement Manufacturers: Market Landscape
Table 26.1 List of Leading Live Biotherapeutic Product and Microbiome Contract Manufacturing Companies
Table 27.1 Osel: Company Snapshots
Table 27.2 Unique Biotech: Company Snapshots
Table 27.3 Meteoric Biopharmaceuticals: Company Snapshots
Table 27.4 Biomedic: Company Snapshots
Table 27.5 Siolta Therapeutics: Company Snapshots
Table 27.6 BiomX: Company Snapshots
Table 27.7 Vedanta Biosciences: Company Snapshots
Table 27.8 Universal Stabilization Technologies: Company Snapshots
Table 27.9 Arranta Bio: Company Snapshots
Table 27.10 Assembly Biosciences: Company Snapshots
Table 27.11 List Biological Laboratories: Company Snapshots
Table 27.12 Luina Bio: Company Snapshots
Table 27.13 WACKER: Company Snapshots
Table 29.1 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Year of Establishment
Table 29.2 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Company Size
Table 29.3 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Location of Headquarters
Table 29.4 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Scale of Operation
Table 29.5 Microbiome Therapeutics Contract Manufacturers: Distribution by Type of Product Manufactured
Table 29.6 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Formulation
Table 29.7 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Scale of Operation and Type of Formulation
Table 29.8 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Primary Packaging Used
Table 29.9 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Formulation and Type of Primary Packaging Used
Table 29.10 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Microbe Used
Table 29.11 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Microbe Used and Location of Headquarters
Table 29.12 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Service Offered
Table 29.13 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Number of Manufacturing Facilities (Region)
Table 29.14 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Number of Manufacturing Facilities (Country)
Table 29.15 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Microbial Species Used
Table 29.16 Live Biotherapeutic Products and Microbiome In-House Manufacturers: Distribution by Year of Establishment
Table 29.17 Live Biotherapeutic Products and Microbiome In-House Manufacturers: Distribution by Company Size
Table 29.18 Live Biotherapeutic Products and Microbiome In-House Manufacturers: Distribution by Location of Headquarters
Table 29.19 Live Biotherapeutic Products and Microbiome In-House Manufacturers: Distribution by Scale of Operation
Table 29.20 Live Biotherapeutic Products and Microbiome In-House Manufacturers: Distribution by Location of Manufacturing Facilities
Table 29.21 Partnerships and Collaborations: Distribution by Year of Partnership
Table 29.22 Partnerships and Collaborations: Distribution by Type of Partnership
Table 29.23 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 29.24 Partnerships and Collaborations: Distribution by Type of Organization
Table 29.25 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Organization
Table 29.26 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 29.27 Most Active Players: Distribution by Number of Partnerships
Table 29.28 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Table 29.29 Partnerships and Collaborations: Local and International Agreements
Table 29.30 Mergers and Acquisitions: Year-wise Cumulative Trend, 2016-2023
Table 29.31 Mergers and Acquisitions: Distribution by Key Value Drivers
Table 29.32 Mergers and Acquisitions: Distribution by Year of Mergers and Acquisitions and Key Value Drivers
Table 29.33 Recent Expansions: Distribution by Year of Expansion
Table 29.34 Recent Expansions: Distribution by Purpose of Expansion
Table 29.35 Recent Expansions: Distribution by Year and Purpose of Expansion
Table 29.36 Recent Expansions: Distribution by Scale of Operation
Table 29.37 Recent Expansions: Distribution by Purpose of Expansion and Scale of Operation
Table 29.38 Recent Expansions: Distribution by Location of Expanded Facility (Region)
Table 29.39 Recent Expansions: Distribution by Location of Expanded Facility (Country)
Table 29.40 Recent Expansions: Distribution by Purpose of Expansion and Location of Expanded Facility (Region)
Table 29.41 Clinical Trial Analysis: Distribution by Trial Registration Year, Pre-2015-2023
Table 29.42 Clinical Trial Analysis: Distribution by Trial Status
Table 29.43 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2015-2023
Table 29.44 Clinical Trial Analysis: Distribution by Trial Phase
Table 29.45 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, Pre-2007-Post-2018
Table 29.46 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, Pre-2015-2023
Table 29.47 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 29.48 Clinical Trial Analysis: Distribution by Type of Sponsor
Table 29.49 Most Active Players: Distribution by Number of Registered Trials
Table 29.50 Clinical Trial Analysis: Distribution by Study Design
Table 29.51 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 29.52 Clinical Trial Analysis: Distribution of Number of Registered Trials by Geography
Table 29.53 Clinical Trial Analysis: Distribution of Number of Registered Trials by Trial Status and Geography
Table 29.54 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Table 29.55 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status and Geography
Table 29.56 Capacity Analysis: Distribution by Company Size
Table 29.57 Capacity Analysis: Distribution by Geography
Table 29.58 Global Installed Live Biotherapeutic Products and Microbiome Contract Manufacturing Capacity in North America
Table 29.59 Global Installed Live Biotherapeutic Products and Microbiome Contract Manufacturing Capacity in Europe
Table 29.60 Global Installed Live Biotherapeutic Products and Microbiome Contract Manufacturing Capacity in Asia-Pacific and Rest of the World
Table 29.61 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Manufacturing, 2023-2035: Distribution by Number of Trials Conducted
Table 29.62 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Manufacturing, 2023-2035: Distribution by Number of Enrolled Patient Population
Table 29.63 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Manufacturing: Distribution by Trial Phase
Table 29.64 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Manufacturing: Distribution by Geography
Table 29.65 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Manufacturing in North America, 2023-2035
Table 29.66 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Manufacturing in Europe, 2023-2035
Table 29.67 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Manufacturing in Asia-Pacific, 2023-2035
Table 29.68 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Manufacturing in Rest of the World, 2023-2035
Table 29.69 Global Commercial Demand for Live Biotherapeutic Products and Microbiome Manufacturing, 2023-2035: Distribution by Number of Target Patient Population (in Million)
Table 29.70 Global Commercial Demand for Live Biotherapeutic Products and Microbiome Manufacturing, 2023-2035 (in cfu)
Table 29.71 Live Biotherapeutic Products and Microbiome CROs: Distribution by Year of Establishment
Table 29.72 Live Biotherapeutic Products and Microbiome CROs: Distribution by Company Size
Table 29.73 Live Biotherapeutic Products and Microbiome CROs: Distribution by Location of Headquarters
Table 29.74 Microbiome Dietary Supplement Manufacturers: Distribution by Year of Establishment
Table 29.75 Microbiome Dietary Supplement Manufacturers: Distribution by Company Size
Table 29.76 Microbiome Dietary Supplement Manufacturers: Distribution by Location of Headquarters
Table 29.77 Global Live Biotherapeutic Products and Microbiome Contract Manufacturing Market, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 29.78 Live Biotherapeutic Products and Microbiome Contract Manufacturing
Table 29.79 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for APIs: (2023-2035) Conservative, Base and Optimistic (USD Million)
Table 29.80 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for FDFs: (2023-2035) Conservative, Base and Optimistic (USD Million)
Table 29.81 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Distribution by Type of Product Formulation, 2023 and 2035 (USD Million)
Table 29.82 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Solid: (2023-2035) Conservative, Base and Optimistic (USD Million)
Table 29.83 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Liquid: (2023-2035) Conservative, Base and Optimistic (USD Million)
Table 29.84 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Others: (2023-2035) Conservative, Base and Optimistic (USD Million)
Table 29.85 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Distribution by Type of Primary Packaging Used, 2023 and 2035 (USD Million)
Table 29.86 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Blister Packs: Future Estimates (2023-2035) Conservative, Base and Optimistic (USD Million)
Table 29.87 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Glass / Plastic Bottles: (2023-2035) Conservative, Base and Optimistic (USD Million)
Table 29.88 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Sachets / Pouches: (2023-2035) Conservative, Base and Optimistic (USD Million)
Table 29.89 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Vials: (2023-2035) Conservative, Base and Optimistic (USD Million)
Table 29.90 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Distribution by Scale of Operation, 2023 and 2035 (USD Million)
Table 29.91 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Clinical: (2023-2035) Conservative, Base and Optimistic (USD Million)
Table 29.92 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Commercial: (2023-2035) Conservative, Base and Optimistic (USD Million)
Table 29.93 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Distribution by Company Size, 2023 and 2035 (USD Million)
Table 29.94 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Small Companies: (2023-2035) Conservative, Base and Optimistic (USD Million)
Table 29.95 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Mid-sized Companies: (2023-2035) Conservative, Base and Optimistic (USD Million)
Table 29.96 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Large and Very Large Companies: (2023-2035) Conservative, Base and Optimistic (USD Million)
Table 29.97 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Distribution by Key Geographical Regions, 2023 and 2035 (USD Million)
Table 29.98 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market in North America: (2023-2035) Conservative, Base and Optimistic (USD Million)
Table 29.99 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market in Europe (2023-2035) Conservative, Base and Optimistic (USD Million)
Table 29.100 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market in Asia-Pacific: (2023-2035) Conservative, Base and Optimistic (USD Million)
Table 29.101 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market in Rest of the World: (2023-2035) Conservative, Base and Optimistic (USD Million)
Table 29.102 Live Biotherapeutic Products and Microbiome Therapeutics Market, Distribution by Leading Developers, 2035

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • 4D Pharma
  • AbbVie
  • ABCO Laboratories
  • ABH Pharma
  • AcuraBio (formerly known as Luina Bio)
  • ADM
  • Advanced Enzymes
  • Allianz Biosciences 
  • Ampersand Capital Partners
  • AmpliPhi Biosciences
  • AOBiome Therapeutics
  • Arena Pharmaceuticals
  • Armata Pharmaceuticals
  • Arranta Bio 
  • AsiaBiome (acquired by Holobiome)
  • Assembly Biosciences
  • AstraZeneca
  • Atlantia Clinical Trials
  • Atlantic Essential Products
  • Aumgene Biosciences
  • Axial Biotherapeutics
  • Axial Therapeutics
  • Azabu University
  • Bacthera (a joint venture of Lonza and Chr Hansen)
  • Bayer 
  • Biena
  • Bifodan 
  • Bio-Me
  • BIOASTER
  • BioCare Copenhagen
  • Biocodex
  • BioGaia
  • Biomcare
  • Biomica
  • Biomillenia
  • Biomodels
  • BiomX
  • Biose Industrie
  • BJP Laboratories
  • Bloom Science
  • Boehringer Ingelheim
  • Brigham and Women’s Hospital
  • Bristol-Myers Squibb
  • C3J Therapeutics
  • Cambridge University Hospitals 
  • Cancer Research UK 
  • Capsugel (acquired by Lonza)
  • Captozyme
  • Cathay Capital
  • Cell Biotech
  • Cerbios-Pharma
  • CHAIN Biotechnology
  • Charles River Laboratories
  • Chr. Hansen
  • Clinical Microbiomics
  • CoreBiome
  • CosmosID
  • Crestovo
  • Crohn’s & Colitis Foundation
  • Custom Probiotics
  • Debiopharm
  • Deerland Probiotics & Enzymes
  • DermBiont
  • Diversigen 
  • DuPont Nutrition & Biosciences
  • Emerge Health
  • EMF
  • Emulate
  • EnteroBiotix
  • Enterome
  • Evelo Biosciences
  • EverImmune 
  • Evologic Technologies
  • EXDEN
  • Exeliom Biosciences
  • Exim Pharma
  • EzBiome
  • Ferring Pharmaceuticals
  • Finch Therapeutics
  • Fonterra
  • FUJIFILM Diosynth Biotechnologies
  • Ganeden Biotech
  • Genetic Analysis
  • GENIBIO
  • Genome & Company
  • Gilead Sciences
  • Ginkgo Bioworks
  • GSK
  • Gustave Roussy 
  • Gusto Global
  • iCarbonX
  • IFF
  • IGEN BIOLAB 
  • Imperial College London
  • Inpac Probiotics 
  • Instituto Biomar
  • Ion Labs
  • John Theurer Cancer Center (a part of Hackensack Universityu Medical Center)
  • Johnson and Johnson
  • JW Nutritional
  • Kaleido Biosciences
  • Karolinska Institutet
  • Karyotica Biologicals
  • Kendy Pharma
  • Kibow Biotech
  • L-GAM
  • Lallemand 
  • Leiden University Medical Center (LUMC)
  • List Biological Laboratories
  • Liveome
  • LNC Therapeutics
  • Locus Biosciences
  • Lonza
  • Luina Bio
  • MaaT Pharma
  • Massachusetts General Hospital
  • Mayo Clinic
  • Medella Naturals
  • Medical University of Graz
  • Memorial Sloan Kettering Cancer Center 
  • Merck
  • MeriCal
  • MetaboGen
  • Meteoric Biopharmaceuticals
  • Microbax
  • Microbiome Insights
  • MicrobiomeDx
  • Microbiotica
  • Mirna Therapeutics
  • Miyarisan Pharmaceutical
  • Molecular Partners AG
  • MRM Health
  • MSD
  • MyBiotics
  • Nestle Health Science
  • New Bellus 
  • NHS 
  • NIZO
  • Norax Supplements
  • North Zealand University Hospital
  • Novo Nordisk
  • NutraScience Labs
  • NYU Langone Medical Center
  • Oncodesign Services
  • Osel
  • OxThera
  • Pace Life Sciences
  • Parkinson’s Institute and Clinical Center
  • Pendulum Therapeutics
  • Pfizer
  • Phylagen
  • Precigen ActoBio
  • Probi
  • ProbioFerm
  • Probiotical
  • Probiotics Australia
  • ProDigest
  • Quay Pharma  
  • Rebiotix
  • Recipharm 
  • Research Institute of St. Joe’s Hamilton 
  • Resphera Biosciences
  • RIKEN
  • Roche
  • RondinX
  • Roswell Park Comprehensive Cancer Center 
  • Ruprecht Karl University of  Heidelberg
  • S-Biomedic
  • Sabinsa
  • Sacco
  • Sanofi
  • SBT Instruments
  • Second Genome
  • Seres Therapeutics
  • Servatus
  • SeylanMED
  • SGS
  • Siolta Therapeutics
  • Sirio Pharma
  • Specialty Enzymes & Probiotics
  • Stanford Cancer Institute
  • Stanford Medicine 
  • Syngen Biotech
  • Synlogic
  • Takeda Pharmaceutical
  • The University of Tokyo
  • Theriva Biologics
  • UAS Labs
  • Unique Biotech
  • University of Adelaide
  • University of Nottingham
  • University of Oxford
  • University of Pennsylvania
  • University of Reading
  • University of Texas MD Anderson Cancer Center
  • Vaiomer
  • Vedanta Biosciences
  • VITA-gen Laboratories
  • Vitakem
  • WACKER
  • Washington University School of Medicine
  • Whiterock Capital
  • Winclove Probiotics
  • YSOPIA Bioscience
  • Zeta Farmaceutici

Methodology

 

 

Loading
LOADING...

Table Information